On Oct 31, major Wall Street analysts update their ratings for $Stryker Corp (SYK.US)$, with price targets ranging from $370 to $420.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and adjusts the target price from $325 to $420.
BofA Securities analyst Travis Steed maintains with a buy rating, and sets the target price at $400.
Citi analyst Joanne Wuensch maintains with a buy rating, and sets the target price at $411.
Barclays analyst Matt Miksic maintains with a buy rating, and adjusts the target price from $402 to $418.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $351 to $370.
Furthermore, according to the comprehensive report, the opinions of $Stryker Corp (SYK.US)$'s main analysts recently are as follows:
The company delivered a strong performance, underscored by an 11.5% organic growth and double-digit expansion across the majority of its significant segments, coupled with better-than-expected operating margins.
Stryker's Q3 outcomes surpassed expectations, demonstrating robust double-digit growth in both revenue and earnings, coupled with an increase in operating margins.
Stryker's recent financial performance exceeded expectations at the top line. Looking ahead to 2025, the company's growth is anticipated to be fueled by a series of new product introductions, the positive impact of mergers and acquisitions with an estimated seven deals poised to contribute to growth, and the ongoing increase in the utilization of Mako, particularly with two new indications. However, a neutral stance is being maintained until there is a clear indication of sales and EPS outperformance compared to the consensus.
Stryker demonstrated robust and varied performance in the third quarter, with revenues reaching $5.494B, surpassing expectations. While the company's implied organic growth rate of 7.5% - 8.0% is below its historical averages for a seasonally strong quarter, it still anticipates healthy procedural dynamics, positive pricing trends, and product development initiatives to maintain its superior growth trajectory.
The recent quarter showed a strong performance for Stryker, with global organic growth picking up pace to hit double digits, a notable positive shift in orthopedic pricing for the first time in ten years, and earnings per share expanding at or above the mid-teen range.
Here are the latest investment ratings and price targets for $Stryker Corp (SYK.US)$ from 15 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
